| lamivudine / Generic mfg. |
ChiCTR-TRC-09000638: A Study on the viral kinetics of different regimes of Pegylated Interferon and Lamivudine combination therapy in HBeAg Positive Chronic Heptatitis B |
|
|
| Completed | N/A | 30 | | PEG-Intron A 100mcq sc once weekly, Lamivudine 100mg QD treatment period 104 weeks (include 32 doses of PEG-Intron A and 96 or 104 weeks Lamivudine) versus one year treatment of Lamivudine 100mg QD | Schering-Plough; None, Hepatitis Research Fund | Viral Diseases | | | | |
ChiCTR-TRC-12002962: A clinical study on Diwuyanggan capsule in treating HBeAg-negative chronic hepatitis B |
|
|
| Completed | N/A | 144 | | Diwuyanggan capsule orally taken three times daily ;Antiviral treatment group:the nucleoside analogues (Entikawei, Adefovir Dipivoxil Tablets, Lamivudine and so on) ;Diwuyanggan capsule and the nucleoside analogues | Hubei province hospital of Traditional Chinese Medicine; Hubei province hospital of traditional Chinese medical, National Natural Science Foundation of China, State Administration of Traditional Chinese Medicine | Chronic hepatitis B | | | | |
ChiCTR-OCH-14004522: Treatment effect and drug-resistant mutations in Chinese AIDS patients switching to second-line antiretroviral therapy |
|
|
| Completed | N/A | 195 | | Tenofovir (TDF) + Kaletra (ritonavir and lopinavir mixture) + lamivudine (3TC)combination antiretroviral therapy ;Tenofovir (TDF) + Kaletra (ritonavir and lopinavir mixture) + lamivudine (3TC)combination antiretroviral therapy | Key Laboratory of AIDS Immunology of National Health and Family Planning Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University; Disease Prevention and Control Center of Henan Province, the Twelfth Five-Year Project on Tackling Key Problems of National Science and Technology (2012ZX10001002-002-013) | AIDS | | | | |
ChiCTR1900024611: Dual therapy with lopinavir/ritonavir plus lamivudine could be an effective alternative for antiretroviral-therapy-naive adults with HIV-1 infection in resource-limited settings: planned 144 week, a randomized, open-label and non-inferiority study from China |
|
|
| Recruiting | N/A | 200 | | Dual-therapy of lopinavir/ritonavir (LPV/r) plus 3TC (DT group) ;triple-therapy regimen containing tenofovir (TDF), 3TC plus efavirenz (EFV) | Guangzhou Eighth People's Hospital; Level of the institution：, no | AIDS | | | | |
| Completed | N/A | 48 | | Tablet; Specification: Each tablet contains 150 mg of ACC007, 300 mg of lamivudine and 300 mg of tenofovir fumarate; it is orally administered on an empty stomach, 1 tablet per cycle, 2 cycles in total. ;Tablet; Specification: ACC007 2 tablets + lamivudine 1 tablet + tenofovir fumarate 1 tablet; oral administration on an empty stomach, 2 tablets per cycle, 2 cycles in total. | Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School; Jiangsu Aidea Pharmaceutical Co., Ltd., Self-financing | HIV/ADIS | | | | |
NCT00476606: A Prospective Cohort of Children With HIV Infection |
|
|
| Active, not recruiting | N/A | 500 | RoW | Zidovudine, Stavudine, Didanosine, Lamivudine, Nevirapine, Efavirenz, LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir | The HIV Netherlands Australia Thailand Research Collaboration, Khon Kaen University | HIV Infections | 06/24 | 06/24 | | |
